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Editorial
Treatments targeting small patient populations:
an important conversation continues
David B. Nash, MD, MBA
Without doubt, lowering prices while increasing ap-
propriate access to pharmaceuticals will remain a hot topic
among health policy makers in the foreseeable future. In
particular, the ongoing debate over the value of drugs and
technologies designed to treat rare conditions will continue
to draw close attention from both the public sector and
mass media.
The Food and Drug Administration (FDA) defines a rare
condition as one that affects fewer than 200,000 Ameri-
cans.1 Generally, these conditions are considered to be se-
vere in nature, progressive, degenerative, life-threatening, or
chronically debilitating. Drugs developed to target rare
conditions are sometimes referred to as orphan drugs. The
Orphan Drug Act of 1983 incentivized pharmaceutical
companies to develop new drugs for rare diseases and ex-
tended those incentives to existing drugs that could be ap-
proved and marketed for different indications and settings.1
As the development rate of orphan drugs and ‘‘niche’’
technologies continue to grow, the discussion tends to focus
solely on the high price tag rather than meaningful efficacy
and value for patients who are affected by these conditions
and the potential cost savings associated with improved
condition management. As a result, new products – even those
associated with incrementally better clinical and quality of life
outcomes than traditional approaches – are frequently viewed
with skepticism.
This supplement offers insights into the complex issues
involved in developing, showing effectiveness, demon-
strating value, and ultimately delivering a life-changing
new product to a small but vulnerable patient population.
The new product described herein was developed specif-
ically for patients suffering from exocrine pancreatic in-
sufficiency (EPI); that is, diseases and conditions that
affect the pancreas – hereditary conditions such as cystic
fibrosis (CF) and acquired conditions such as chronic
pancreatitis. Because of a lack of adequate pancreatic di-
gestive enzymes, patients with EPI experience clinical
symptoms related to malabsorption of fat. Many of these
patients must rely on enteral nutrition (EN) to avoid
malnutrition – especially patients with acute pancreatitis
and/or pancreatic cancer, children with CF, patients in
intensive care units (ICUs), patients with intestinal failure,
and infants in neonatal ICUs.
None of the currently available pancreatic enzyme re-
placement therapies (PERT) are formulated for or indi-
cated for use in patients receiving EN for several reasons.
PERT capsules are not FDA approved for use with EN
formulas. The ‘‘work-around’’ of adding crushed capsules
to EN formula is contrary to practice guidelines and inter-
rupts feedings by clogging the tube. Further, the capsules are
not indicated for overnight EN because their activity peaks
at 30 minutes and wanes thereafter.2 Most importantly,
even when PERT capsules are administered in large doses,
there is no evidence of normal fat absorption in patients
receiving EN. (In fact, patients receiving EN were excluded
from participating in the clinical trials that led to FDA
approval of PERTs.) Consequently, many patients with EPI
who follow this regimen continue to struggle nutritionally
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and experience clinical symptoms related to malabsorption
of fats.
Developed to optimize treatment for the population of
tube-fed patients with fat malabsorption, RELiZORB
(immobilized lipase) is a novel hybrid technology – an
in-line digestive cartridge designed specifically for hy-
drolyzing fats in enteral formulas. Easily administered
without risk of clogging feeding tubes, the product has
been shown to break down more than 90% of fats in EN
formulas throughout overnight feedings.3 Ample real-
world clinical evidence has shown improved tolerability
and improved fatty acid absorption with positive outcomes
reported in terms of weight gain and increased patient
compliance with oral nutrition.4 In fact, Cystic Fibrosis
Centers using this technology to treat CF patients receiv-
ing EN have documented actual weight gain and increased
body mass index (BMI).5–7
We’ve all heard it said that technology generates value
only if the health benefit outweighs the cost. Herein lies the
next hurdle – getting a firm grasp on costs. The direct costs
associated with traditional EN are significant ($80 to $200
per day for formula, tube feeding supplies, and PERT), and
the outcomes achieved are suboptimal (CF patients who
receive EN achieve only 60% of normal fat levels). Like
patients with other EPI-related conditions, hospitalization
becomes necessary when malabsorption becomes malnutri-
tion. In-hospital costs of EN include medical professional
time spent crushing and adding PERTs to feeding bags,
unclogging feeding tubes, and addressing unresolved patient
symptoms.
Like many innovative products, this one doesn’t fit the
typical payer reimbursement model. Although the FDA
was clear in classifying the cartridge as a medical device,
there has been ongoing debate around reimbursement (ie,
whether to classify this as a medical device [because of the
cartridge delivery mechanism] or a drug [because of the
immobilized lipase delivered via the cartridge]). Payers
consistently reimburse providers for standard therapies –
even those that, like traditional EN regimens, often fail to
achieve the intended goal. In this case, use of a new
technology may optimize EN, enable patients to achieve
nutritional goals, reduce or eliminate the need for PERT
during tube feedings, and ultimately reduce avoidable costs
associated with frequent hospitalizations and increased
length of stay.
As I see it, targeted innovative therapy is the new re-
ality, one with unimaginable promise for subpopulations
of patients who struggle with relatively rare conditions.
All stakeholders must accept responsibility for cutting
through the politics to clear the pathway and get the right
products and new technologies to the right people at the
earliest opportunity. It was with this in mind that we
worked with the developers of RELiZORB to convene
the national expert advisory board meeting described
herein.
Introduction
Overview of exocrine pancreatic insufficiency (EPI)
and related issues
The pancreas, an essential part of the gastrointestinal (GI)
system, is functionally composed of exocrine and endocrine
constituents. Because there is minimal anatomic separation
of the exocrine and endocrine pancreatic function, disease
states that cause disruption or damage in one component of
the organ may lead to defects in the other component.8
EPI is a relatively uncommon but severe condition that is
associated with a variety of complex disorders such as cystic
fibrosis (CF), pancreatic cancer, gastric/pancreatic surgery,
short bowel syndrome, and chronic pancreatitis. Physiological
and biochemical effects of EPI include decreased production
and secretion of lipase, increased lipase destruction and deg-
radation, and GI motility disorders. The deficiency in pan-
creatic enzymes (lipase, amylase, protease) results in impaired
digestion and subsequent absorption of all nutrients, fats and
fat-soluble vitamins being the most clinically relevant.8
Steatorrhea, diarrhea, weight loss, abdominal discom-
fort, and bloating are hallmarks of EPI. In addition to
lifestyle modification (eg, alcohol abstinence, frequent
low-volume meals), the typical treatment for EPI is pan-
creatic enzyme replacement therapy (PERT), the clinical
efficacy of which is inconsistent.9 Left untreated, or in-
adequately controlled, the condition leads to increasingly
severe GI symptoms, reduced caloric intake, and inability
to gain and/or maintain weight, placing the patient at risk
for malnutrition.
Malabsorption of fats dramatically increases the risk for
malnutrition in patients with EPI.10 Because malnutrition
further compromises treatment for the medical conditions
underlying EPI, enteral nutrition (EN) becomes a vital ther-
apeutic intervention for stabilizing body mass index (BMI) in
some cases.3 EN formulas contain fats as well as carbohy-
drates, proteins, vitamins, and minerals to help prevent or
address nutritional deficiencies related to malabsorption.
Nutrition support therapy is more complex than com-
monly appreciated, particularly when prescribed for patients
with EPI. Severely pancreatic insufficient patients are un-
able to digest and absorb long-chain triglycerides contained
in EN formulas – particularly healthy fats such as doc-
osahexanoic acid (DHA) and eicosapentaenoic acid (EPA).
Currently, there is no published evidence to support the use
of any Food and Drug Administration (FDA)-approved
PERT products in enteral feedings, and existing clinical
guidelines do not support administration of enzymes by
mixing them into EN formulas.3 Factors such as care set-
tings and nutritional formula types must be considered on a
case-by-case basis, and complications must be anticipated
and avoided; for example, the use of crushed PERT capsule
contents in enteral feedings, or capsule contents adminis-
tered directly though the feeding tube, causes tube clogging
and requires frequent monitoring.11
From the patient perspective, some with CF rely on noc-
turnal EN for adequate caloric intake to maintain and hope-
fully improve BMI and lung function. Following pancreatic
and other GI surgeries, EN is essential for patients who ex-
perience gastroparesis and are unable to tolerate oral meals.
Lacking an appetite for food, patients with pancreatic cancer
often use EN to prevent cachexia. EN is helpful for some
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patients with cerebral palsy who experience pain while eating
solid food.
Novel approach to addressing challenges of nutritional
support therapy for patients with EPI - Eric First, MD,
Alcresta Therapeutics
For the population of patients who require EN because
they lack the natural ability to sufficiently hydrolyze and
absorb dietary fats, there is a compelling need that is inad-
equately addressed by current medical practice. Alcresta
Therapeutics developed a unique enzyme-based hybrid
product in order to fill this treatment gap. The RELiZORB
(immobilized lipase) enzyme cartridge focuses on the crit-
ical need for fat hydrolysis in EN when administered to
patients with EPI. The product is specifically designed to
address the challenges faced by patients living with serious
conditions such as CF, pancreatitis, pancreatic cancer, and
severe digestive disorders. Indicated for use in pediatric
patients (ages 5 years and older) and adults to hydrolyze fats
in enteral formula, the product is now used by more than 63
US hospitals primarily for patients with CF who receive EN.
CF affects*30,000 children and adults in the United States,
and *11% of these patients require EN to increase energy
intake in hopes of increasing weight and BMI, both of which
are correlated with pulmonary outcomes (lung function
expressed as FEV1).12
Purpose of expert advisory board meeting
By improving care efficiency and clinical outcomes for
patients receiving nutrition support for EPI, the digestive
enzyme cartridge also assists in improving the quality of
care and patient quality of life. Both clinical studies and
real-world evidence have demonstrated the product’s ef-
fectiveness as a chronic condition management tool for this
complex population of patients who do not have a viable
alternative.
Information regarding the value of this product and the
consequential implications under new reimbursement and
care delivery paradigms has yet to reach mainstream health
care providers and payers. Chief among the challenges are
payer issues (eg, ‘‘lack of medical necessity’’ and ‘‘inves-
tigational’’ determinations, prior authorization and appeal
requirements, adjudication as a device rather than a phar-
maceutical). The Centers for Medicare & Medicaid Services
bundled the product under an enteral supply billing code
when it was launched; however, as of May 2018, only 25%
of the cost was reimbursed for patients with private insur-
ance. Alcresta is working to help patients maintain access to
the product.
An Expert Advisory Board Meeting was convened jointly
by Alcresta, Inc., and the Jefferson College of Population
Health to increase awareness of the potential value of the
product – from a clinical quality, cost-effectiveness, and
patient outcomes perspective – among important stake-
holder communities and engage experts in constructive di-
alogue around broadening the dissemination of information
to providers and payers.
Expert advisors
Joseph Boullata, PharmD, RPh, FASPEN, FACN -
Clinical Professor in Nutrition Sciences at Drexel Uni-
versity; Pharmacy Specialist in Nutrition Support at
Hospital of the University of Pennsylvania; research and
publications in the areas of nutrition, gastroenterology,
and critical care.
David C. Evans, MD, FACS, PNS - Director of
Nutrition Support Services, Trauma Medical Director,
and Associate Professor of Surgery at The Ohio State
University Wexner Medical Center in Columbus, OH.
Robert S. Gregory, RPh, MS, MBA - Consultant
with extensive industry knowledge and experience in
managed care, long-term care, and hospital pharmacy;
recent managed care organization experience as Phar-
macy Director for Aetna Pharmacy Management.
Winifred S. Hayes, RN, PhD, ANP - Founder, Pre-
sident, and CEO of Hayes, Inc.; Board of Directors for
Utilization Review Accreditation Commission (URAC);
first President of the National Association of Independent
Review Organizations.
Jeffery Lerner, PhD - President Emeritus of Emer-
gency Care Research Institute (ECRI), a designated
Evidence-based Practice Center by the US Agency for
Healthcare Research and Quality and listed as a Patient
Safety Organization by the US Department of Health &
Human Services.
Edith Mitchell, MD, FACP, FCCP - Researcher in
pancreatic cancer and other GI malignancies whose
work involves new drug evaluation and chemotherapy,
development of new therapeutic regimens, chemo-
radiation strategies for combined modality therapy,
patient selection criteria, and supportive care for pa-
tients with GI cancer.
Gary M. Owens, MD - Strategic and tactical con-
sulting services to pharmaceutical manufacturers, new
technology developers, employer benefit managers and
managed care plans.
Leslie Schechter, PharmD - Advanced Practice
Pharmacist specializing in Pain Management and
Nutritional Support at Thomas Jefferson University
Hospital.
Joseph M. Sinopoli, RPh - Managed Care Pharmacy
Director/Formulary Ops Specialist assisting with the
formulary development, reimbursement and contracting
process; currently working with a large regional health
plan and a major pharmacy benefits manager.
Virginia A. Stallings, MD - Professor of Pediatrics
at the University of Pennsylvania Perelman School of
Medicine; Cortner Chair in Gastroenterology and
Nutrition and Director of the Nutrition Center at The
Children’s Hospital of Philadelphia, Philadelphia, PA.
Kay Vavrina, RD, LD, CNSC - 20 years’ experience
in clinical dietetics with more than 8 years specializing in
Cystic Fibrosis Nutrition; University of Texas Health,
San Antonio Cystic Fibrosis Center; lecturer in Nutrition
and Biology departments at the University of Texas San
Antonio.
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Meeting Proceedings
On May 11, 2018, a panel of experts was convened at the
Jefferson College of Population Health in Philadelphia, PA,
to provide multi-stakeholder perspectives on this innovative
product in terms of its potential role in optimizing clinical
and cost outcomes for the population of patients who require
EN support for the treatment of EPI.
Understanding nutrition support and nutritional
pharmacotherapy – Joseph Boullata, PharmD, RPh
Nutrition support therapy is a complex process – from
patient assessment and prescribing, to administration and
monitoring – involving multiple providers, thereby in-
creasing the risk for errors. In general, the goal of nutrition
support including EN is to prevent or address malnutrition in
patients who are unable to eat or meet daily energy demands
via oral intake alone.
Malnutrition is an acute, subacute, or chronic state of nu-
trition in which a combination of varying degrees of over-
nutrition or undernutrition, with or without inflammatory
activity, have led to a change in body composition and di-
minished function. Affecting 20%-50% of hospitalized adult
patients, malnutrition is associated with untoward conse-
quences including increased length of stay and resource uti-
lization and heightened risk for readmission, infection, and
overall mortality.13,14 A state of malnutrition is routinely
documented in the presence of 2 or more of the following:
unintentional weight loss, decreased muscle mass, decline in
functional status, insufficient energy intake, decreased sub-
cutaneous fat mass, and accumulation of fluid.15,16
EN refers to the system of providing nutrition directly
into the GI tract, bypassing the oral cavity. An important
therapeutic intervention for a variety of clinical indications,
EN includes adult, pediatric, and infant nutrient formulas.
Appropriate use of EN incorporates practices that maximize
patient benefit while minimizing adverse events. Although it
is commonly associated with acute care, rehabilitation, and
long-term care settings, *438,000 patients use EN in the
home setting; one third of these patients use it for ‡5
years.17 This often includes administration during the night
to allow freedom of movement during the day.
The EN intervention begins with the selection of a formula
to meet patients’ energy, protein, and fluid needs relative to
their clinical status. The formula recommendation is fully
documented and discussed with the prescriber and treatment
team. Once implemented, EN must be monitored for clinical
complications and frequent challenges. For example, when
best practices are not followed, feeding tubes can easily be-
come clogged with EN formula and/or drug residue.18
Any alteration of a commercially available drug dosage
form affects the timing of drug delivery into the GI tract and
its clinical effect. Ideally, enteral medications should be pre-
pared in the pharmacy but, in practice, they often are prepared
by hospital nurses or patients/caregivers in the home setting.
The potential consequences of drug handling errors (eg, un-
suitable drug formulation, improper preparation method) can
lead to serious consequences – from tube clogging and ther-
apeutic failure to drug toxicity and death.18 Although nearly
all of those who prepare and administer drugs via EN are
confident that their technique is appropriate and effective,
observational studies show that error rates approach 60%.19
For example, patients with CF requiring PERT are often
prescribed an oral PERT product, sometimes referred to by its
generic term pancrelipase. Like similar FDA-approved
products, pancrelipase is a delayed release capsule. The
product should not be crushed and, if granules are added
directly to enteral formula, the liquid binds to the enteric
coating and the feeding tube becomes clogged. To decrease
the incidence of clumping, some resources recommend sus-
pending the granules in thickened water, juice, or applesauce.
Mixing granules with EN formula may cause the enzymes
to begin activating prior to administration.11 Dissolving
granules in sodium bicarbonate solution is sometimes ef-
fective, but there is no evidence that this approach improves
the breakdown and absorption of nutrients in EN formu-
las.11,20 The result in each case is the inadequate delivery of
nutrition to the patient.
The clinical science of RELiZORB – Archie Stone, PhD
Malnutrition often occurs secondarily to other conditions.
Effective treatment of malnutrition helps patients cope with
their primary conditions. Aside from intestinal failure, CF is
the chief, and perhaps the most challenging, of the condi-
tions with secondary risk for malnutrition because of EPI
and fat malabsorption that are associated with the condition.
Published data from the CF Foundation patient registry in
addition to numerous publications dating back to the 1980s
have suggested a strong relationship between lung function
and a healthy BMI in patients with CF.21 The data show that
maintaining a healthy nutrition status is critical to main-
taining or improving lung function for these patients. As
nutrition status deteriorates (measured in terms of BMI), a
patient’s lung function decreases, thereby increasing the
frequency and severity of pulmonary exacerbations that
result in hospitalization and increased health resource uti-
lization.22 Health care staff at today’s CF treatment centers
are tasked with identifying and addressing signs of malnu-
trition in patients with CF at every clinical visit. Although
oral meals, snacks, and supplementation are adequate to
meet the daily caloric demands for a majority of these pa-
tients, *11% become malnourished and require overnight
EN to achieve a healthy BMI.
The RELiZORB immobilized lipase enzyme cartridge
was developed to help maximize the effectiveness EN for
these patients and other chronically ill patients with EPI-
associated conditions. As shown in Figure 1, the cartridge is
connected in-line between the formula bag and the feeding
tube. This allows the fat hydrolysis to occur ex vivo.
Evidence from 2 prospective clinical trials encompassing
*2% of the total CF tube feeding population demonstrate
normalization of fatty acids in plasma and tissue as well as a
reduction in GI events with use of RELiZORB.4,23 A longer
term 90-day study showed a trend of improved clinical
outcomes, with 61% of patients having improvement in
weight z-scores and percentiles. In addition, improvement in
BMI and reduction of GI adverse events without PERTs
during EN feeding has been documented.23
Study 497,4 a multicenter, double-blind, crossover study
with an open label safety evaluation period, evaluated the
efficacy and safety of the product in CF patients receiving
EN. At entry into the study, the 34 patients used on average
8.5 PERT capsules per tube feeding and had baseline fatty
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acid plasma levels significantly below those of healthy indi-
viduals despite receiving EN for a mean 6.6 years. Results
showed that use of the cartridge resulted in a statistically
significant 2.8-fold increase in fat absorption vs. placebo,
fewer reported GI events irrespective of PERT use, and im-
proved tolerability vs. baseline (Figure 2). Investigators re-
ported that use of the cartridge was associated with a 57%
reduction in the incidence of diarrhea. In addition, more
participants reported preservation of appetite and breakfast
consumption when using the digestive cartridge compared
with their pre-study regimens. This likely was because of an
increase in fat absorption from EN and an associated decrease
in the frequency and severity of symptoms of malabsorption.
The ASSURE Study (498),23 a long-term, 90-day study
demonstrated significantly improved fat absorption in terms
of increases in red blood cell levels of DHA+EPA (an indi-
cator of tissue uptake), improved omega-6/omega-3 ratios,
and increases in plasma levels of DHA+EPA (Figure 3). Use
of the cartridge raised omega-3 fatty acid levels in both
plasma and erythrocytes (surrogate for tissue uptake) and
improved nutritional parameters among children and adults
with CF receiving EN. Although the changes were not sta-
tistically significant from baseline to 90 days, 61% of pa-
tients in the study experienced improvements in weight, and
BMI z-scores and percentiles over the course of the study.
Real-world evidence is accruing from multiple children’s
hospitals regarding the effectiveness of the product in im-
proving outcomes for children with CF.
 C. S. Mott Children’s Hospital, University of Michigan
Health System: A retrospective chart review of 17 pa-
tients (age range 1–20 years, average age 11.5 years)
prescribed the product for at least 3 months showed im-
provement in symptoms associated with fat malabsorption
in 76% of patients: 53% reported less greasy and odifer-
ous stools; 29% reported fewer abdominal aches; 18%
reported less nausea, bloating, and vomiting; and 18%
reported less frequent bowel movements. Importantly, a
3-fold improvement in weight-for-age z-score was noted
during the period when patients were using the product
compared to the 3 months prior to starting therapy. The
authors concluded, ‘‘The findings show that using an
immobilized lipase cartridge is feasible and is associated
with clinically significant positive outcomes.’’5
 Nationwide Children’s Hospital: A retrospective chart
review of 19 patients (age range 1–29 years, average
age 14 years) assessed nutrition outcomes including z-
scores for weight and BMI 6 months prior to and 6
months following use of the product. There was a
positive but not statistically significant trend in growth
rates after starting the product. Caregivers and patients
reported that the system was easy to use and had a
positive impact on important quality of life parameters
(ie, improved appetite the following day, fewer adverse
GI symptoms, less sleep interruption [no need to wake
to take enzymes]). The authors concluded, ‘‘The use of
the enzyme cartridge simplifies a mundane process,
potentially eliminating the need for additional enzyme
replacement during enteral feeds.’’24
 Medical University of South Carolina (MUSC) Chil-
dren’s Hospital: A retrospective chart review was con-
ducted for 13 pediatric patients (mean age 8.3 years)
using the product in place of traditional PERT with
overnight EN feedings. The product was started when
EN was initiated for 4 of the patients; the other 9 patients
had been receiving EN for a mean of 3.4 years before the
product was initiated. Although these patients continued
to use PERT with oral intake, none of the patients had
used PERT in conjunction with overnight tube feedings.
Results showed resolution of GI symptoms in 6 of the
patients. At 3 months, 10 patients experienced improved
BMI or weight-for-length percentiles; at 6 months, 5
patients showed improvement in BMI percentile com-
pared to baseline. The authors concluded that, ‘‘RE-
LiZORB use was well tolerated, and promoted weight
gain and reduction in GI symptoms of malabsorption in
children age 3 months to 16 years, even in the absence of
traditional PERT with EN.’’6
Perhaps the most compelling real-world evidence is
documented in the case report of a 2-year-old boy with CF
and short bowel syndrome.7 Despite all attempts to manage
the boy’s unusually severe symptoms by traditional means
(ie, enteral feedings with crushed PERT products via
FIG. 1. Enteral feeding system and detail of RELiZORB
enzyme cartridge.
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gastric- or gastro-jejunal feeding tube), he continued to
experience symptoms of malabsorption along with poor
weight gain and growth. Overnight home nursing assistance
was required for his treatment regimen because of poor
tolerance of EN feedings.
At 23–24 months of age, PERT was stopped and RE-
LiZORB was initiated. Prior to introducing the cartridge, the
boy’s weight had never been higher than the 15th percentile.
From 23–32 months of age, he gained 3.62 kg, with an
improvement in his weight-for-age percentile from the <2nd
to the 31st percentile. A concurrent gain in his length im-
proved his length-for-age percentile from the <2nd to the 5th
percentile. By 32 months of age, he reached the 82nd per-
centile for BMI for his age.
Patient perspective
Via a telephone interview with the expert advisors, a 29-year-
old woman shared her experience as a person with CF who
requires EN. She reported that being unable to digest food is
‘‘painful and very unpleasant.’’ After resisting it for many
years, she opted to try EN when her weight dropped sharply in
2017. At first, she used specialized formulas with PERT every 2
hours. This interrupted her sleep, made her feel too full to eat
breakfast, and did not help her gain weight. Now using a
standard formula with RELiZORB, she reports that the car-
tridge is very easy to use, that she sleeps through the night, and
that she has more energy for engaging in activities. Importantly,
she has achieved her goal weight with a gain of 10 pounds.
FIG. 2. RELiZORB study 497 results: plasma absorption profile and Cmax for total docosahexaenoic acid (DHA), baseline
adjusted.
EPA, eicosapentaenoic acid; RBC, red blood cell.
Source: Freedman S, Ornstein D, Black P, Brown P, McCoy K, Stevens J, Grujic D, Clayton R. Increased fat absorption
from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr
2017;65:97–101. https://journals.lww.com/jpgn/FullText/2017/07000/Increased_Fat_Absorption_From_Enteral_Formula
.22.aspx. Reprinted with permission.
FIG. 3. ASSURE Study results: Changes in erythrocyte membrane fatty acid composition (%) for omega-3 index ITT
(intention to treat) population as measured by gas chromatography-mass spectrometry.
DHA, docosahexamoic acid; EPA, eicosapentaenoic acid; SEM, standard error of mean.
Source: Stevens J, Wuatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and safety with sustained use of
RELiZORB evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding. J Pediatr Gastroenterol
Nutr 2018;67:527–532. https://journals.lww.com/jpgn/Fulltext/2018/10000/Absorption_and_Safety_With_Sustained_Use_
of.21.aspx. Reprinted with permission.
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Before using the cartridge, she required treatment with
corticosteroids and other drugs to improve her lung function.
Since using the digestive cartridge, she believes that her
‘‘body is now fueled to fight infections’’ and that her overall
health has improved.
Value proposition of RELiZORB – Amy Connor, MPH,
Jim Gamgort, Alcresta Therapeutics
RELiZORB is the only FDA-cleared product that hy-
drolyzes fat in EN formula, thereby maximizing the in-
tended benefit of the feeding (ie, reduced GI events,
improved appetite, normalization of critical fatty acid levels,
optimal use of other nutrients, improvement in weight gain
[demonstrated in clinical trials and real-world evidence],
reduction in PERT use). Adoption of the product has been
excellent among clinicians working with CF patients in
select inpatient settings. Consistently positive patient-
reported outcomes are indicative of the product’s value to
those suffering from EPI.
Although the digestive cartridge appears to be cost neutral
versus current treatment practice and the associated reduc-
tion in GI adverse events is life-changing for patients, costs
continue to escalate and the company must build additional
evidence of the product’s added value.
Results of an independent analysis clearly demonstrated
a cost-savings opportunity compared with current un-
proven treatment practice (ie, crushed PERT capsules
added to EN formula) for inpatient usage. Advisors sug-
gested using hospital/inpatient data to make the case for
value. There are hidden costs that may not be readily as-
sessed (eg, additional time for nurses to frequently monitor
and clear clogged tubing).
Payment for the product remains challenging. There is
concern among payers about the cost – especially for pa-
tients on Medicaid or receiving disability benefits – when, in
fact, the product may result in long-term savings as a result
of improved health status that is secondary to good nutrition.
In the absence of formal written policy, payers tend to deny
prior authorization requests for the product on the basis of
‘‘lack of medical necessity’’ and being ‘‘experimental/in-
vestigational.’’ Experts noted that the appeals process is
very expensive for payers. They suggested that the company
share their data showing that almost 100% of denials are
overturned when appealed in a timely fashion.
Discussion: key observations and recommendations
from the expert panel
The following are key points from expert panel discus-
sions that explored the technology in multiple contexts and
considered various approaches to better communicating in-
formation regarding this novel product and improving ac-
cess to it for target patient populations.
Nutrition support considerations
Intravenous (parenteral) nutrition is one of the most
complicated treatments used by physicians when the enteral
route no longer meets a patient’s caloric needs. This high-
risk therapy is best avoided in favor of EN when the GI tract
is available, but even EN must be closely managed to pre-
vent clinical complications and practice challenges. Among
the latter, clogged EN feeding tubes are still not rare oc-
currences; these events should be tracked to assure quality
of care.
There is very little provider reimbursement for EN care,
and there often is no designated health care provider to
oversee its use for patients using EN at home.
Product use considerations
Experts agreed that the concept and the delivery mecha-
nism make sense. Real-world evidence has demonstrated
that people have gained weight and that their symptoms
decreased. The product should be considered for use in all
patients with EPI who receive EN for ‡5 years. It will be
important to determine how to measure compliance when
the product is used on an outpatient basis.
The focus for further investigation should be on identi-
fying all of the conditions associated with EPI (other than
CF) in which EN may be indicated (eg, chronic pancreatitis,
pancreatic cancer) as well as potential inpatient and inten-
sive care applications. The company should consider col-
lecting and presenting appropriate data at the right
professional meetings to communicate evidence of safety
and effectiveness. Also consider recruiting an expert to
present evidence to select professional audiences and
disease-specific patient populations.
Understand the entire universe of people who are
tube fed
Focusing on the science, consider all conditions associ-
ated with, or not associated with, EPI. Because CF is one of
the most complex conditions, perhaps the CF data could be
extrapolated to other conditions. Pancreatic cancer patients
are very sick but their overall GI tracts are relatively heal-
thy. What is the measure for improvement in longevity
versus better quality of life? Explore the product’s effec-
tiveness for patients with celiac disease, a non-EPI condi-
tion, given the underlying factors. Also consider nutritional
support in the context of end of life.
Emphasize separate strategies for inpatient and outpatient
populations. If use of the product is expanded in the inpa-
tient setting, some aspects will translate to the outpatient
setting. Focus on premature infants in terms of weight gain
and earlier hospital discharge.
Build new patient registries and make use of existing
ones to build further evidence
The population of patients with metastatic pancreatic
cancer who may benefit from the digestive cartridge can be
readily identified via existing pancreatic cancer data reg-
istries. Seventy-five percent of these patients are inopera-
ble at the time of diagnosis, and those who undergo
chemotherapy prior to surgery may benefit from EN using
the product.
Experts agreed that more population-based data would
enhance current evidence. A registry function should be a
top priority. Options include contacting centers that main-
tain registries (eg, pancreas tumor registries, post-Whipple
surgery registries) and starting a company registry to
capture data from all conditions associated with EPI to
augment randomized clinical trials and to provide addi-
tional insights.
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Do the best quality research possible
The evidence shows that the product improves nutrient
digestion and absorption. From a clinical trial perspective,
continue to build the evidence base by designing and con-
ducting longer term studies with outcome measures such as
improved weight gain (lean body mass) and improved
functionality using simple tools (eg, grip strength, BMI).
There are ample data and real-world evidence showing
efficacy of the digestive cartridge when used by patients
with CF. Extend research beyond CF and focus on devel-
oping peer-reviewed scientific evidence. For example:
 A combined, multicenter retrospective analysis of pa-
tient outcomes in conditions other than CF.
 A prospective randomized study incorporating the 2018
standard of care and embedding patient-reported out-
comes.
 Patient selection criteria are vital. Use the end point of
correcting fat malabsorption across different condi-
tions, and identify patient-focused end points such as
weight gain.
Additional comments: Look more closely at the relation-
ship between good nutrition, modulated inflammation, and
functional outcome. Also, consider different kinds of studies
(eg, workforce savings studies, a survey of why payers care).
Work with professional organizations toward
developing guidelines and standards of care
Product inclusion in CF treatment guidelines (eg, defining
the criteria used to diagnose malnutrition, explaining how to
adjust dosage per feeding) is the near-term solution to as-
suring coverage and providing access for the CF population.
The CF Foundation does not update guidelines frequently;
propose the development of a supplement to the EN
guideline. Also, it would be helpful if the CF Foundation
was to write a letter to professional organizations about
incorporating the product into guidelines.
As new studies are published, lobby professional orga-
nizations and ask payers to have their Health Technology
Assessment groups review new data and update their
summaries.
Work with gastroenterologists to incorporate relevant
information in the GI guidelines. This will lead eventually to
the product being included in more hospital formularies.
Work with payers
Data showing that denials are regularly overturned on
appeal are meaningful to payers. Incorporate these in pre-
sentations. Develop prior authorization policy guidelines for
the product to share with payers.
In the current fragmented market many payers do not
cover the product, and much of the cost is absorbed by the
company. Enter into dialogue with select payers about
conditional coverage as additional evidence is developed.
Work with private payers toward adjudicating the product as
a drug rather than a device. (This may not be possible with
all payers as some have very clear pathways for claim ad-
judication based on FDA clearance pathways.)
Help payers understand which of their patient popula-
tions would benefit from the product. Clearly define the
level of fat malabsorption at which EN is justified (eg, for
pancreatic cancer patients). Create sample prior authori-
zation scenarios by which payers can easily identify the
subpopulations of patients who would be eligible for the
product.
National Committee for Quality Assurance policies re-
quire health plans to reassess technologies periodically. Ask
payers to update their policies pertaining to EN and add the
product to the list of permitted investigational drugs.
Among the approaches that the company might take to
make the value case for payers are:
 Increase the number of patients and subpopulations,
clarify which patients would use the product, and help
payers determine benefit designs.
 Limit payer risk by executing creative guaranteed or
‘‘capped,’’ value-based contracts with meaningful
outcome measures. A cost ceiling for patients could be
included.
 Consider the value of patient-reported outcomes. Sur-
vey nurses regarding the challenges associated with
traditional EN and the number of diarrhea episodes that
patients with malabsorption of fats experience.
Understand and expand the market
Develop good data around growing the market. Introduce
the product in the metastatic pancreatic cancer patient
population. These patients have difficulty taking large
amounts of oral medications with food; they are seeking
something to help. Design a short-term outcome study –
75% of these patients already have a feeding tube in place.
Consider broader implications and applications for the
product as the research base expands to include chronic
pancreatitis, intensive care unit patients, and select onco-
logical conditions.
Reach out to integrated health care delivery systems. The
Veterans Administration is interested in working with the
private sector and would be a different constituency. Also
work toward Medicaid coverage for the product.
Engage with natural advocates
Dietitians and nurses are critical team members in the
nutrition universe; they are the standard bearers. Dietitians
are valuable resources because they see – and refer – all
patients.
As nutrition champions, clinicians will begin to order the
product once they are aware of it. A quick, easy-to-administer
test to screen for malnutrition would be helpful to clinicians.
Continue to refine the product
From an engineering perspective, focus on the device
design, flow rates, and hydrolysis relative to different pop-
ulations and different formulations. Importantly, foresee
where and how the product will be used 2–3 years from
now.
Work with patients
As employer groups shift more costs to patients via co-
insurance and co-pays, patients are making more decisions.
Patients who are given the opportunity to use the product
will be fearful of losing access related to payer denials. The
CF Foundation offers patients a stipend to help cover co-
pays.
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Look into the success rate of a pro-patient care ‘‘hub’’ –
these are limited with respect to cancer, but incentivize
providers to treat patients with CF holistically.
Conclusion
Although new drugs and technologies are being devel-
oped to improve the medical management and clinical
outcomes for populations of patients with rare conditions,
payment determinations often are based solely on the price
tag rather than the value for patients and the potential cost
savings associated with improved condition management.
The RELiZORB (immobilized lipase) enzyme cartridge was
developed for the population of patients who lack the natural
ability to sufficiently hydrolyze and absorb dietary fats and
who require supplemental EN – specifically, patients with
conditions such as CF, pancreatitis, pancreatic cancer, and
severe digestive disorders. The enzyme cartridge is the only
FDA-cleared product that safely and effectively hydrolyzes
fat in EN formula, as demonstrated by clinical trials and
real-world evidence.
In May 2018, an Expert Advisory Board was convened. The
broad range of stakeholder perspectives included: clinicians
specializing in nutrition, pediatrics, gastroenterology, critical
care, trauma, long-term care, and oncology; commercial pay-
ers such as managed care organizations and self-insured em-
ployers; nutrition scientists; and patients. Following a review
of the evidence for RELiZORB and the value proposition for
the product, the experts recommended taking various ap-
proaches to increase appropriate physician prescribing of, pa-
tient access to, and payer reimbursement for this unique
product that targets a rare but very serious chronic condition.
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